Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment

Genomics

Volumn 102, Issue 3, 2013, Pages 157-162

  Huang, Donghui ^a   Kim, Dong Wan ^b   Kotsakis, Athanasios ^c   Deng, Shibing ^a   Lira, Paul ^a   Ho, Steffan N ^a   Lee, Nathan V ^a   Vizcarra, Pamela ^a   Cao, Joan Q ^a   Christensen, James G ^a   Kim, Tae Min ^b   Sun, Jong mu ^d   Ahn, Jin Seok ^d   Ahn, Myung Ju ^d   Park, Keunchil ^d   Mao, Mao ^a  

^a PFIZER INC   (United States)

^b Seoul National University Hospital   (South Korea)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Crizotinib; Deep sequencing; Mutation; Resistance

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; GENOMIC DNA;

ADRENAL METASTASIS; ALK GENE; AMINO ACID SUBSTITUTION; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; DNA BARCODING; DNA DETERMINATION; EML4 GENE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ALGORITHM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MUTATIONAL ANALYSIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TUMOR BIOPSY;

CRIZOTINIB; DEEP SEQUENCING; MUTATION; RESISTANCE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SEQUENCE ANALYSIS, DNA;

EID: 84882668835     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2013.02.006     Document Type: Article

References (19)

1. Camidge D.R., Bang Y., Kwak E.L., Shaw A.T., Iafrate A.J., Maki R.G., Solomon B.J., Ou S.I., Salgia R., Wilner K.D., Costa D.B., Shapiro G., LoRusso P., Stephenson P., Tang Y., Ruffner K., Clark J.W. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2011, 29:2501. (ASCO meeting abstracts).
2. Crinò L., Kim D., Riely G.J., Janne P.A., Blackhall F.H., Camidge D.R., Hirsh V., Mok T., Solomon B.J., Park K., Gadgeel S.M., Martins R., Han J., De Pas T.M., Bottomley A., Polli A., Petersen J., Tassell V.R., Shaw A.T. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): profile 1005. J Clin Oncol. 2011, 29:7514. (Suppl., ASCO meeting abstracts).
3. Palmer R.H., Vernersson E., Grabbe C., Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J. 2009, 420:345-361.
4. Soda M., Takada S., Takeuchi K., Choi Y.L., Enomoto M., Ueno T., Haruta H., Hamada T., Yamashita Y., Ishikawa Y., Sugiyama Y., Mano H. A mouse model for EML4-ALK-positive lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19893-19897.
5. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J., Richards W.G., Sugarbaker D.J., Ducko C., Lindeman N., Marcoux J.P., Engelman J.A., Gray N.S., Lee C., Meyerson M., Jänne P.A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008, 14:4275-4283.
6. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., Zhou W., Choi H.G., Smith S.L., Dowell L., Ulkus L.E., Kuhlmann G., Greninger P., Christensen J.G., Haber D.A., Settleman J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008, 68:3389-3395.
7. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., Yatabe Y., Takeuchi K., Hamada T., Haruta H., Ishikawa Y., Kimura H., Mitsudomi T., Tanio Y., Mano H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 2010, 363:1734-1739.
8. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., Kondo K.L., Linderman D.J., Heasley L.E., Franklin W.A., Varella-Garcia M., Camidge D.R. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012, 18(5):1472-1482. (Mar 1).
9. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., Jessop N.A., Wain J.C., Yeo A.T., Benes C., Drew L., Saeh J.C., Crosby K., Sequist L.V., John Iafrate A., Engelman J.A. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4:120ra17.
10. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., Lathan C., Marcoux J.P., Du J., Okuda K., Capelletti M., Shimamura T., Ercan D., Stumpfova M., Xiao Y., Weremowicz S., Butaney M., Heon S., Wilner K., Christensen J.G., Eck M.J., Wong K.K., Lindeman N., Gray N.S., Rodig S.J., Jänne P.A. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011, 71(18):6051-6060. (Sep 15).
11. Thomas R.K., Baker A.C., Debiasi R.M., Inckler W., Laframboise T., Lin W.M., Wang M., Feng W., Zander T., MacConaill L., Lee J.C., Nicoletti R., Hatton C., Goyette M., Girard L., Majmudar K., Ziaugra L., Wong K.K., Gabriel S., Beroukhim R., Peyton M., Barretina J., Dutt A., Emery C., Greulich H., Shah K., Sasaki H., Gazdar A., Minna J., Armstrong S.A., Mellinghoff I.K., Hodi F.S., Dranoff G., Mischel P.S., Cloughesy T.F., Nelson S.F., Liau L.M., Mertz K., Rubin M.A., Moch H., Loda M., Catalona W., Fletcher J., Signoretti S., Kaye F., Anderson K.C., Demetri G.D., Dummer R., Wagner S., Herlyn M., Sellers W.R., Meyerson M., Garraway L.A. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 2007, 39(3):347-351. (Mar).
12. Thelwell N., Millington S., Solinas A., Booth J., Brown T. Mode of action and application of scorpion primers to mutation detection. Nucleic Acids Res. 2000, 28(19):3752-3761.
13. Dufort S., Richard M.J., de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal. Biochem. 2009, 391(2):166-168. (Aug 15).
14. Dressman D., Yan H., Traverso G., Kinzler K.W., Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(15):8817-8822.
15. Hindson B.J., Ness K.D., Masquelier D.A., Belgrader P., Heredia N.J., Makarewicz A.J., Bright I.J., Lucero M.Y., Hiddessen A.L., Legler T.C., Kitano T.K., Hodel M.R., Petersen J.F., Wyatt P.W., Steenblock E.R., Shah P.H., Bousse L.J., Troup C.B., Mellen J.C., Wittmann D.K., Erndt N.G., Cauley T.H., Koehler R.T., So A.P., Dube S., Rose K.A., Montesclaros L., Wang S., Stumbo D.P., Hodges S.P., Romine S., Milanovich F.P., White H.E., Regan J.F., Karlin-Neumann G.A., Hindson C.M., Saxonov S., Colston W. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 2011, 83:8604-8610.
16. Ardini E., Galvani A. ALK inhibitors, a pharmaceutical perspective. Front Oncol. Cancer Mol. Targets Ther. 2012, 2(17):1-8.
17. Camidge D.R., Doebele R.C. Treating ALK-positive lung cancer-early successes and future challenges. Nat. Rev. Clin. Oncol. 2012, 9(5):268-277.
18. Kim S., Kim T.M., Kim D.W., Go H., Keam B., Lee S.H., Ku J.L., Chung D.H., Heo D.S. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J. Thorac. Oncol. 2013, (Jan 22).
19. Li H., Handsaker B., Wysoker A., Fennell T., Ruan J., Homer N., Marth G., Abecasis G., Durbin R., Genome Project Data Processing Subgroup 1000. The Sequence alignment/map (SAM) format and SAMtools. Bioinformatics 2009, 25:2078-2079.